You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -1,701.4% | -1,099.7% |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -14.8 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 228.7 | 114.3 |
| Price / Book value | 5.7 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 32.9% | -61.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 15.3% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2018-04-30 | 0.63 | -8.93 | -7.91p | -6.0 | 0.0 | n/a | n/a | 0.0% |
| 2019-04-30 | 0.68 | -10.87 | -6.56p | -11.6 | 0.0 | n/a | n/a | 0.0% |
| 2019-12-31 | 0.58 | -9.04 | -6.88p | -9.1 | 0.0 | n/a | n/a | 0.0% |
| 2020-12-31 | 0.76 | -13.74 | -6.52p | -7.3 | 0.0 | n/a | n/a | 0.0% |
| 2021-12-31 | 1.01 | -17.36 | -6.67p | -17.8 | 0.0 | n/a | n/a | 0.0% |
| Angle's Parsortix to be used in 'significant' prostate cancer study Sharecast News | 20 May |
|---|---|
| Angle agrees pharma services contract with new customer Sharecast News | 28 Jul |
| Price Monitoring Extension | 25-May-22 16:38 |
|---|---|
| ANGLE receives FDA clearance for Parsortix | 25-May-22 12:32 |
| Prostate Cancer UK funds new study using Parsortix | 20-May-22 07:00 |
| Preliminary Results | 28-Apr-22 07:00 |
| Notice of Preliminary Results and Webcast | 20-Apr-22 07:00 |